How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,367 results for

Cushing Response

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. A Case of Cushing's Syndrome due to Ectopic Adrenocorticotropic Hormone Secretion from Esthesioneuroblastoma with Long Term Follow-Up after Resection (PubMed)

A Case of Cushing's Syndrome due to Ectopic Adrenocorticotropic Hormone Secretion from Esthesioneuroblastoma with Long Term Follow-Up after Resection We present a case of a 52-year-old male who developed Cushing's Syndrome due to ectopic adrenocorticotrophic hormone (ACTH) secretion from a large esthesioneuroblastoma (ENB) of the nasal sinuses. The patient initially presented with polyuria, polydipsia, weakness, and confusion. Computed tomography scan of the head and magnetic resonance imaging (...) ENB. Postoperatively, his ACTH level dropped below the limit of detection. In the ensuing 4 months, he underwent adjuvant chemoradiation with carboplatin and docetaxel with good response and resolution of hypokalemia and hyperglycemia, with no sign of recurrence as of 30 months postoperatively. His endogenous cortisol production is rising but has not completely recovered.

Full Text available with Trip Pro

2018 Case reports in endocrinology

22. Open-label Treatment in Cushing's Syndrome

Cortendo AB More Information Go to Layout table for additonal information Responsible Party: Cortendo AB ClinicalTrials.gov Identifier: Other Study ID Numbers: COR-2017-OLE First Posted: August 8, 2018 Last Update Posted: March 19, 2019 Last Verified: October 2018 Layout table for additional information Studies a U.S. FDA-regulated Drug Product: Yes Studies a U.S. FDA-regulated Device Product: No Additional relevant MeSH terms: Layout table for MeSH terms Syndrome Cushing Syndrome Pituitary ACTH (...) Open-label Treatment in Cushing's Syndrome Open-label Treatment in Cushing's Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Open-label Treatment in Cushing's Syndrome (OPTICS) The safety

2018 Clinical Trials

23. Extension Study to Evaluate the Safety and Clinical Benefit of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

the maximum number of saved studies (100). Please remove one or more studies before adding more. Extension Study to Evaluate the Safety and Clinical Benefit of Long-Term Use of Relacorilant in Patients With Cushing Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our (...) for details. ClinicalTrials.gov Identifier: NCT03604198 Recruitment Status : Recruiting First Posted : July 27, 2018 Last Update Posted : July 27, 2018 See Sponsor: Corcept Therapeutics Information provided by (Responsible Party): Corcept Therapeutics Study Details Study Description Go to Brief Summary: This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study

2018 Clinical Trials

24. Patient and Partner Perception After Remission of Cushing's Syndrome

Perception After Remission of Cushing's Syndrome (CUSHING) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03607474 Recruitment Status : Recruiting First Posted : July 31, 2018 Last Update Posted : August 14, 2018 See Sponsor (...) Patient and Partner Perception After Remission of Cushing's Syndrome Patient and Partner Perception After Remission of Cushing's Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Patient and Partner

2018 Clinical Trials

25. Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699

Study in Patients With Endogenous Cushing's Syndrome for LCI699 The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03606408 Recruitment Status : Recruiting First Posted : July 30, 2018 Last Update Posted : March 26, 2019 See (...) Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699 Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699 - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Roll-over

2018 Clinical Trials

26. The Risk of Adrenal Insufficiency and Cushing Syndrome Associated With Glucocorticoid Therapy in People With Chronic Inflammatory Diseases

Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. The Risk of Adrenal Insufficiency and Cushing Syndrome Associated With Glucocorticoid Therapy in People With Chronic Inflammatory Diseases The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov (...) The Risk of Adrenal Insufficiency and Cushing Syndrome Associated With Glucocorticoid Therapy in People With Chronic Inflammatory Diseases The Risk of Adrenal Insufficiency and Cushing Syndrome Associated With Glucocorticoid Therapy in People With Chronic Inflammatory Diseases - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study

2018 Clinical Trials

27. Muscle in Acromegaly and Cushing's Syndrome

Pau Information provided by (Responsible Party): Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau Study Details Study Description Go to Brief Summary: Cushing's syndrome (CS) and acromegaly determine myopathy and muscle weakness which persist long-term after control of hormone excess. Fatty infiltration in skeletal muscle (myosteatosis) is associated with muscle atrophy, frailty, and increased morbidity and mortality in several human models. The study is aimed at evaluating (...) Muscle in Acromegaly and Cushing's Syndrome Muscle in Acromegaly and Cushing's Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Muscle in Acromegaly and Cushing's Syndrome (MAC) The safety

2018 Clinical Trials

28. Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease

of Seliciclib (R-roscovitine) for Cushing Disease The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03774446 Recruitment Status : Recruiting First Posted : December 13, 2018 Last Update Posted : December 13, 2018 See Sponsor (...) : Cedars-Sinai Medical Center Information provided by (Responsible Party): Shlomo Melmed, MD, Cedars-Sinai Medical Center Study Details Study Description Go to Brief Summary: This phase 2 multicenter, open-label clinical trial will evaluate safety and efficacy of 4 weeks of oral seliciclib in patients with newly diagnosed, persistent, or recurrent Cushing disease. Funding Source - FDA Office of Orphan Products Development (OOPD) Condition or disease Intervention/treatment Phase Cushing Disease Drug

2018 Clinical Trials

29. Tumor-directed therapeutic targets in Cushing disease. (PubMed)

ClinicalTrials.gov with a search for "Cushing disease."At present, the tumor-targeted pharmacological therapy of CD is concentrated on dopamine agonists (cabergoline) and somatostatin analogs (pasireotide) with varying efficacy, escape from response, and considerable side effects. Preclinical studies on corticotroph pathophysiology have brought forward potential drugs such as retinoic acid, silibinin, and roscovitine, whose efficacy and safety remain to be determined.For many patients with CD, effective tumor (...) Tumor-directed therapeutic targets in Cushing disease. The most frequent cause of endogenous hypercortisolism is Cushing disease (CD), a devastating condition associated with severe comorbidities and high mortality. Effective tumor-targeting therapeutics are limited.Search in PubMed with key words "corticotroph" and "Cushing's disease" plus the name of the mentioned therapeutic agent and in associated references of the obtained papers. Additionally, potential therapeutics were obtained from

2018 Journal of Clinical Endocrinology and Metabolism

30. A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome

for the Treatment of Endogenous Cushing's Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03053271 Recruitment Status : Recruiting First Posted : February 15, 2017 Last Update Posted : February 15, 2019 See Sponsor: Millendo (...) Therapeutics US, Inc. Information provided by (Responsible Party): Millendo Therapeutics, Inc. ( Millendo Therapeutics US, Inc. ) Study Details Study Description Go to Brief Summary: This is a Phase 2 multicenter, randomized, double-blind, placebo controlled study of ATR-101 to evaluate the efficacy and safety of orally-administered ATR-101 in adults with endogenous Cushing's syndrome. Following wash-out (if needed), all eligible subjects will enter an open-label intra-subject dose-escalation period of 8

2017 Clinical Trials

31. Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment

. Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03080181 Recruitment Status : Completed First Posted : March 15, 2017 Last Update Posted : October 27, 2017 Sponsor: University of Palermo Information provided by (Responsible (...) Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2017 Clinical Trials

32. Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome

or more studies before adding more. Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03379363 Recruitment Status : Recruiting (...) First Posted : December 20, 2017 Last Update Posted : December 20, 2017 See Sponsor: Corcept Therapeutics Information provided by (Responsible Party): Corcept Therapeutics Study Details Study Description Go to Brief Summary: This retrospective, multi-center, chart review study will collect patient data from medical charts of pediatric patients who have been treated with Korlym for Cushing's syndrome. Condition or disease Hypercortisolism Cushing Syndrome Detailed Description: This retrospective

2017 Clinical Trials

33. Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's Disease

number of saved studies (100). Please remove one or more studies before adding more. Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's Disease (IMPEC) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our (...) for details. ClinicalTrials.gov Identifier: NCT03346954 Recruitment Status : Not yet recruiting First Posted : November 20, 2017 Last Update Posted : November 21, 2017 See Sponsor: Hospices Civils de Lyon Information provided by (Responsible Party): Hospices Civils de Lyon Study Details Study Description Go to Brief Summary: Cushing's disease is characterized by the existence of a benign pituitary tumor developed from corticotropic cells responsible for excessive ACTH secretion. This results

2017 Clinical Trials

34. The Circadian Rhythm in CusHing SyndrOme in Active Phase and dUring RemiSsion (TheHOURS)

before adding more. The Circadian Rhythm in CusHing SyndrOme in Active Phase and dUring RemiSsion (TheHOURS) (TheHOURS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03343470 Recruitment Status : Recruiting First Posted (...) The Circadian Rhythm in CusHing SyndrOme in Active Phase and dUring RemiSsion (TheHOURS) The Circadian Rhythm in CusHing SyndrOme in Active Phase and dUring RemiSsion (TheHOURS) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies

2017 Clinical Trials

35. Affective alterations in patients with Cushing's syndrome in remission are associated with decreased BDNF and cortisone levels. (PubMed)

Affective alterations in patients with Cushing's syndrome in remission are associated with decreased BDNF and cortisone levels. Affective alterations and poorer quality of life often persist in patients with Cushing's syndrome (CS) in remission. Brain-derived neurotrophic factor (BDNF) regulates the hypothalamic-pituitary-adrenal axis (HPA) and is highly expressed in brain areas controlling mood and response to stress. Our aims were to assess affective alterations after long-term remission

Full Text available with Trip Pro

2017 European Journal of Endocrinology

36. Stereotactic Radiosurgery for Cushing's Disease: Results of an International, Multicenter Study. (PubMed)

Stereotactic Radiosurgery for Cushing's Disease: Results of an International, Multicenter Study. Cushing disease (CD) due to adrenocorticotropic hormone-secreting pituitary tumors can be a management challenge.To better understand the outcomes of stereotactic radiosurgery (SRS) for CD and define its role in management.International, multicenter, retrospective cohort analysis.Ten medical centers participating in the International Gamma Knife Research Foundation.Patients with CD with >6 months (...) endocrine follow-up.SRS using Gamma Knife radiosurgery.The primary outcome was control of hypercortisolism (defined as normalization of free urinary cortisol). Radiologic response and adverse radiation effects (AREs) were recorded.In total, 278 patients met inclusion criteria, with a mean follow-up of 5.6 years (0.5 to 20.5 years). Twenty-two patients received SRS as a primary treatment of CD. Mean margin dose was 23.7 Gy. Cumulative initial control of hypercortisolism was 80% at 10 years. Mean time

Full Text available with Trip Pro

2017 Journal of Clinical Endocrinology and Metabolism

37. Adrenal Cushing's syndrome during pregnancy. (PubMed)

Adrenal Cushing's syndrome during pregnancy. Cushing syndrome (CS) during pregnancy is a rare condition with only a few cases reported in the literature. Misdiagnosis of CS is common because of overlapping features like fatigue, weight gain, striae and emotional changes that can occur during normal pregnancy. Changes in maternal hormones and their binding proteins complicate assessment of glucocorticoid hormone levels during gestation. CS during pregnancy is most frequently due to an adrenal (...) adenoma and to a lesser degree to adrenocorticotropic hormone (ACTH) hypersecretion by a pituitary adenoma. Furthermore, aberrant expression of luteinizing hormone (LH) receptors in the adrenal cortex has been suggested to be involved in the pathogenesis of adrenal CS during pregnancy. We report three pregnant women with ACTH-independent Cushing's syndrome and an adrenal tumor. After uncomplicated delivery, patient 1 underwent in vivo testing for aberrant hormone receptor expression by the adenoma

Full Text available with Trip Pro

2017 European Journal of Endocrinology

38. Histone deacetylase inhibition attenuates hepatic steatosis in rats with experimental Cushing's syndrome (PubMed)

Histone deacetylase inhibition attenuates hepatic steatosis in rats with experimental Cushing's syndrome Cushing's syndrome (CS) is a collection of symptoms caused by prolonged exposure to excess cortisol. Chronically elevated glucocorticoid (GC) levels contribute to hepatic steatosis. We hypothesized that histone deacetylase inhibitors (HDACi) could attenuate hepatic steatosis through glucocorticoid receptor (GR) acetylation in experimental CS. To induce CS, we administered adrenocorticotropic (...) by VPA. Pan-HDACi and an HDAC class I-specific inhibitor, but not an HDAC class II a-specific inhibitor, attenuated dexamethasone (DEX)-induced lipogenesis in HepG2 cells. The transcriptional activity of Fasn was decreased by pretreatment with VPA. In addition, pretreatment with VPA decreased DEX-induced binding of GR to the glucocorticoid response element (GRE). Treatment with VPA increased the acetylation of GR in ACTH-infused rats and DEX-induced HepG2 cells. Taken together, these results indicate

Full Text available with Trip Pro

2017 The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology

39. A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.

studies (100). Please remove one or more studies before adding more. A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov (...) : SONICS STUDY COMPLETERS: Completed the final SONICS visit (M12) and have demonstrated maintenance of clinical response on a stable Therapeutic Dose of levoketoconazole for at least 12 weeks prior to study entry. ALL OTHERS: Confirmed newly diagnosed, persistent or recurrent endogenous Cushing's syndrome of any etiology, except secondary to malignancy (including pituitary or adrenal carcinoma). Elevated mean 24-hour UFC levels at least 1.5X upper limit of the normative range of the study's central

2017 Clinical Trials

40. Quality of Life, Fatigue and Cognitive, Affective and Emotional Dysfunction in Patients With Cushing's Syndrome

studies (100). Please remove one or more studies before adding more. Quality of Life, Fatigue and Cognitive, Affective and Emotional Dysfunction in Patients With Cushing's Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov (...) such as hippocampus and frontal cortex 2 years after treatment of Cushing syndrome by using structural MRI Functional brain response [ Time Frame: 2 years ] Changes in brain functional connectivity during rest and during testing of cognitive and emotional functioning 2 years after treatment of Cushing syndrome by using functional MRI Glucose utilization [ Time Frame: 2 years ] Change in glucose utilization in the hippocampus and frontal cortex 2 years after treatment of Cushing syndrome by using Fludeoxyglucose

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>